Please use this identifier to cite or link to this item:
|Title:||Brain-Penetrating Angiotensin-Converting Enzyme Inhibitors and Cognitive Change in Patients with Dementia due to Alzheimer's Disease|
|Authors:||Oliveira, Fabricio Ferreira de [UNIFESP]|
Bertolucci, Paulo Henrique Ferreira [UNIFESP]
Chen, Elizabeth Suchi [UNIFESP]
Smith, Marilia de Arruda Cardoso [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
|Citation:||Journal of Alzheimers Disease. Amsterdam: Ios Press, v. 42, p. S321-S324, 2014.|
|Abstract:||Controversy over benefits of angiotensin-converting enzyme inhibitors (ACEIs) for treatment of dementia due to Alzheimer's disease (AD) led to this alternative investigational approach by the employment of pharmacogenetic methods, correlating the cognitive change of patients with late-onset AD with the presence of common ACE gene promoter polymorphisms, and stratifying the sample in groups of patients who responded or not to the brain-penetrating ACEIs Captopril or Perindopril. A trend was found for treatment with brain-penetrating ACEIs to slow cognitive decline in AD patients with the haplotype rs1800764 (CC): rs4291 (TT) (p = 0.024), and also non-significantly for independent carriers of rs1800764 or rs4291.|
|Appears in Collections:||Artigo|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.